Raymond James & Associates Novo Cure LTD Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	SELL	$40.29 - $82.51 $305,317 - $625,260	-7,578 Reduced 47.88%	8,250 $342,000
Q1 2023 Apr 14, 2023	SELL	$56.44 - $118.81 $40,975 - $86,256	-726 Reduced 4.39%	15,828 $951,000
Q4 2022 Feb 08, 2023	SELL	$63.98 - $85.37 $72,937 - $97,321	-1,140 Reduced 6.44%	16,554 $1.21 Million
Q3 2022 Oct 25, 2022	SELL	$67.99 - $89.57 $53,848 - $70,939	-792 Reduced 4.28%	17,694 $1.34 Million
Q2 2022 Aug 12, 2022	SELL	$56.6 - $89.9 $188,308 - $299,097	-3,327 Reduced 15.25%	18,486 $1.29 Million
Q1 2022 May 11, 2022	SELL	$60.15 - $84.52 $51,368 - $72,180	-854 Reduced 3.77%	21,813 $1.81 Million
Q4 2021 Feb 08, 2022	BUY	$75.08 - $121.99 $260,002 - $422,451	3,463 Added 18.03%	22,667 $1.7 Million
Q3 2021 Nov 02, 2021	BUY	$116.17 - $194.55 $95,724 - $160,309	824 Added 4.48%	19,204 $2.23 Million
Q2 2021 Aug 11, 2021	BUY	$130.4 - $225.58 $231,720 - $400,855	1,777 Added 10.7%	18,380 $4.08 Million
Q1 2021 May 14, 2021	SELL	$124.11 - $190.17 $4.99 Million - $7.65 Million	-40,215 Reduced 70.78%	16,603 $2.2 Million
Q4 2020 Feb 12, 2021	BUY	$112.16 - $174.14 $4.24 Million - $6.59 Million	37,836 Added 199.33%	56,818 $9.83 Million
Q3 2020 Nov 04, 2020	SELL	$58.05 - $111.31 $332,394 - $637,361	-5,726 Reduced 23.17%	18,982 $2.11 Million
Q2 2020 Jul 28, 2020	BUY	$57.2 - $74.41 $431,860 - $561,795	7,550 Added 44.0%	24,708 $1.47 Million
Q1 2020 Apr 21, 2020	SELL	$57.05 - $95.75 $84,376 - $141,614	-1,479 Reduced 7.94%	17,158 $1.16 Million
Q4 2019 Feb 12, 2020	BUY	$68.3 - $93.8 $197,865 - $271,738	2,897 Added 18.41%	18,637 $1.57 Million
Q3 2019 Nov 07, 2019	BUY	$61.86 - $97.8 $658,004 - $1.04 Million	10,637 Added 208.45%	15,740 $1.18 Million
Q2 2019 Aug 06, 2019	BUY	$42.22 - $63.23 $8,486 - $12,709	201 Added 4.1%	5,103 $323,000
Q1 2019 May 06, 2019	SELL	$31.96 - $56.12 $70,663 - $124,081	-2,211 Reduced 31.08%	4,902 $236,000
Q4 2018 Feb 11, 2019	BUY	$28.72 - $52.63 $49,226 - $90,207	1,714 Added 31.75%	7,113 $238,000
Q3 2018 Nov 14, 2018	BUY	$32.0 - $52.4 $172,768 - $282,907	5,399 New	5,399 $283,000

Others Institutions Holding NVCR

# of Institutions

264

Shares Held

76.5M

Call Options Held

1.17M

Put Options Held

318K

Black Rock Inc. New York, NY

12.1M
Shares

$288 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

11.8M
Shares

$281 Million
0.0% of portfolio
Capital International Investors Los Angeles, CA

7.92M
Shares

$188 Million
0.02% of portfolio
Capital World Investors Los Angeles, CA

4.31M
Shares

$102 Million
0.01% of portfolio
Nordwand Advisors, LLC Radnor, PA

3.03M
Shares

$72 Million
12.67% of portfolio

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.49B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account